ZimVie (NASDAQ:ZIMV) Issues FY 2024 Earnings Guidance

ZimVie (NASDAQ:ZIMV) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided EPS guidance of 0.550-0.700 for the period, compared to the consensus EPS estimate of 0.590. The company issued revenue guidance of $450.0 million-$460.0 million, compared to the consensus revenue estimate of $453.9 million.

ZimVie Stock Performance

NASDAQ:ZIMV traded down $3.10 during midday trading on Friday, hitting $17.30. The company’s stock had a trading volume of 1,723,003 shares, compared to its average volume of 426,869. ZimVie has a fifty-two week low of $6.52 and a fifty-two week high of $22.40. The firm’s 50 day moving average is $18.05 and its 200-day moving average is $17.54. The company has a debt-to-equity ratio of 1.32, a current ratio of 2.68 and a quick ratio of 2.23. The firm has a market cap of $472.12 million, a P/E ratio of -1.24 and a beta of 2.18.

ZimVie (NASDAQ:ZIMV) last issued its quarterly earnings results on Thursday, August 1st. The company reported $0.13 earnings per share for the quarter. The company had revenue of $116.81 million for the quarter. ZimVie had a negative net margin of 63.84% and a positive return on equity of 2.09%. During the same quarter last year, the company posted $0.17 EPS. Equities analysts anticipate that ZimVie will post 0.63 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC raised their price objective on shares of ZimVie from $20.00 to $23.00 and gave the stock a buy rating in a research note on Friday.

About ZimVie

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.